Contineum Therapeutics Inc. Class A Common Stock (CTNM)

About CTNM

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

51

Website

www.contineum-tx.com

Fundamentals

1-day range

$14.1$15.66

Market cap

$599.30M

P/E (trailing)

—

P/E (forward)

-7.81

EPS (trailing)

$-1.72

Dividend yield

—

Beta

0.74

Avg. volume

361.1K

Forecasts

7 analyst ratings

Contineum Therapeutics Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• CTNM

  Contineum Therapeutics Inc. Class A Common Stock

  $17.05

  ▼ 1.16%
  Market cap $599.30MP/E —
  $7.26$16.91
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $592.31MP/E 3.53
  $6.13$14.96
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $569.09MP/E —
  $9.1$40.43
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $552.33MP/E —
  $8.72$27.41
• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33
• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $520.04MP/E 62.96
  $6.97$14.51

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• These stocks are moving in today's pre-market session
  ChartMill · 8/13/2026
• 12 Health Care Stocks Moving In Thursday's Pre-Market Session
  Benzinga · 8/13/2026
• RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
  Benzinga · 7/31/2026

• Carmine N. Stengone · August 3, 2026 · Option Exercise

  2.5K @ $1.01
• Carmine N. Stengone · August 3, 2026 · Sale

  2.5K @ $16.01
• Daniel S. Lorrain · July 9, 2026 · Option Exercise

  25 @ $1.01
• Daniel S. Lorrain · July 9, 2026 · Sale

  25 @ $16
• Daniel S. Lorrain · July 8, 2026 · Option Exercise

  1.0K @ $1.01
• Daniel S. Lorrain · July 8, 2026 · Sale

  1.0K @ $16
• Carmine N. Stengone · July 8, 2026 · Option Exercise

  2.5K @ $1.01
• Carmine N. Stengone · July 8, 2026 · Sale

  2.5K @ $16
• Daniel S. Lorrain · July 1, 2026 · Option Exercise

  4.2K @ $1.01
• Daniel S. Lorrain · July 1, 2026 · Sale

  2.5K @ $16.24
• Daniel S. Lorrain · July 1, 2026 · Sale

  5.9K @ $15.67
• Daniel S. Lorrain · June 30, 2026 · Option Exercise

  28.8K @ $1.01
• Daniel S. Lorrain · June 30, 2026 · Sale

  28.8K @ $16.04
• Tim Watkins · June 30, 2026 · Option Exercise

  10.8K @ $4.5
• Tim Watkins · June 30, 2026 · Sale

  10.8K @ $16.02

Institutional Ownership

March 31, 2026

Total shares held

30.39M

Total value held

$395.60M

Institutional holders

86